BioAge Labs (BIOA) Cash from Financing Activities (2023 - 2026)

BioAge Labs has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $123.7 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $123.7 million, up 8347.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $136.7 million (down 35.43% YoY), and the FY2025 annual result was $11.5 million, down 96.99% from the prior year.
• Cash from Financing Activities came in at $123.7 million for Q1 2026 at BioAge Labs, up from $16.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q3 2024 to a low of -$2.4 million in Q2 2024.
• The 4-year median for Cash from Financing Activities is $7.5 million (2023), against an average of $51.5 million.
• Across the five-year window, Cash from Financing Activities plunged 100.89% in 2025 and soared 8347.67% in 2026, its largest moves.
• BioAge Labs' Cash from Financing Activities stood at -$1.0 million in 2023, then jumped by 2567.99% to $24.9 million in 2024, then plunged by 35.7% to $16.0 million in 2025, then surged by 672.59% to $123.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $123.7 million (Q1 2026), $16.0 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.